Tumor Biology

, Volume 36, Issue 4, pp 2685–2694 | Cite as

SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma

  • Yong Liu
  • Xuegang Luo
  • Jingyu Deng
  • Yuan Pan
  • Li Zhang
  • Han Liang
Research Article

Abstract

SET and MYND domain-containing protein 3 (SMYD3), a histone methyltransferase, plays a key function in the progression of human cancer. However, the role of SMYD3 in gastric carcinoma carcinogenesis has yet to be elucidated. This study aimed to determine the relationships of SMYD3 expression with clinicopathological characteristics and prognosis in gastric carcinoma. The expression of SMYD3 was detected by real-time quantitative reverse transcription PCR and Western blot in gastric carcinoma (GC) cell lines, normal gastric mucosa cell line, GC tissues, and adjacent non-tumor tissues. SMYD3 expression in tissue sections of 180 gastric carcinoma samples were evaluated using immunohistochemistry. The staining results were compared with clinicopathological characteristics and to the outcome of patients. The expression levels of SMYD3 messenger RNA (mRNA) and protein in GC tissues were both higher than those in adjacent non-tumor tissues (p < 0.05). SMYD3 mRNA and protein expression levels were higher in GC cell lines MKN28, SGC7901, and MGC803 than normal gastric mucosa cell line GES-1. SMYD3 expression in gastric carcinoma was significantly correlated with primary tumor size (p < 0.001), lymph node metastasis (p < 0.001), and TNM stage (p = 0.011). Degree of differentiation [hazard ratio (HR) = 5.113; p = 0.006], serosal invasion (HR = 2.074; p = 0.024), lymph node metastasis (HR = 1.354; p < 0.001), and SMYD3 expression (HR = 0.564; p = 0.004) were identified as the independent factors of the overall survival (OS) in all enrolled GC patients. For patients with positive lymph node metastasis, degree of differentiation (HR = 5.974; p = 0.015), lymph node metastasis (HR = 1.257; p < 0.001), and SMYD3 expression (HR = 0.529; p = 0.004) were the independent prognostic factors of the OS. SMYD3 performed an important function in the aggressiveness of gastric carcinoma and may act as a promising target for prognostic prediction.

Keywords

Stomach Neoplasm SMYD3 Prognosis 

Notes

Acknowledgments

This work was supported by National Natural Science Foundation of China (No. 31470816).

Conflicts of interest

None

References

  1. 1.
    Jaskelioff M, Peterson CL. Chromatin and transcription: histones continue to make their marks. Nat Cell Biol. 2003;5:395–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol. 2003;15:172–83.CrossRefPubMedGoogle Scholar
  3. 3.
    Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004;6:731–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Xu S, Wu J, Sun B, Zhong C, Ding J. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding. Nucleic Acids Res. 2011;39:4438–49.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jakowlew SB, Breathnach R, Jeltsch JM, Masiakowski P. Chambon P sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res. 1984;12:2861–78.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, Nagayasu T, Shibuya M, Nakamura Y, Furukawa Y. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res. 67:10759–10765.Google Scholar
  8. 8.
    Luo XG, Xi T, Guo S, Liu ZP, Wang N, Jiang Y, et al. Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells. IUBMB Life. 2009;61:679–84.CrossRefPubMedGoogle Scholar
  9. 9.
    Dong SW, Zhang H, Wang BL, Sun P, Wang YG, Zhang P. Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma. Oncol Rep. 2014;32:1064–70.PubMedGoogle Scholar
  10. 10.
    Sponziello M, Durante C, Boichard A, Dima M, Puppin C, Verrienti A, et al. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. Mol Cell Endocrinol. 2014;392:8–13.CrossRefPubMedGoogle Scholar
  11. 11.
    Chen LB, Xu JY, Yang Z, Wang GB. Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration. World J Gastroenterol. 2007;13:5718–24.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006;97:113–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Wang SZ, Luo XG, Shen J, Zou JN, Lu YH, Xi T. Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro. BMB Rep. 2008;41:294–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Kim H, Heo K, Kim JH, Kim K, Choi J, An W. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol Chem. 2009;284:19867–77.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Yuan Y. A survey and evaluation of population-based screening for gastric cancer. Cancer Biol Med. 2013;10:72–80.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Yang L. Incidence and mortality of gastric carcinoma in China. World J Gastroenterol. 2006;12:17–20.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang XM, Zhou C, Gu H, Yan L, Zhang GY. Correlation of RKIP, STAT3 and cyclin D1 expression in pathogenesis of gastric cancer. Int J Clin Exp Pathol. 2014;7:5902–8.PubMedPubMedCentralGoogle Scholar
  18. 18.
    He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z, et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol. 2012;43:1425–35.CrossRefPubMedGoogle Scholar
  19. 19.
    Cock-Rada AM, Medjkane S, Janski N, Yousfi N, Perichon M, Chaussepied M, et al. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 2012;72:810–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Ren TN, Wang JS, He YM, Xu CL, Wang SZ, Xi T. Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells. Med Oncol. 2011;28:S91–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang SZ, Luo XG, Shen J, Zou JN, Lu YH, Xi T. Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cells growth and invasion in vitro. BMB Rep. 2008;41:294–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Zou JN, Wang SZ, Yang JS, Luo XG, Xie JH, Xi T. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. Cancer Lett. 2009;280:78–85.CrossRefPubMedGoogle Scholar
  23. 23.
    Wang XQ, Miao X, Cai Q, Garcia-Barcelo MM. Fan STSMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population. Exp Oncol. 2007;29:71–3.PubMedGoogle Scholar
  24. 24.
    Hundahl SA, Phillips JL, Menck HR. The national cancer data base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth edition American joint committee on cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921–32.CrossRefPubMedGoogle Scholar
  25. 25.
    Abe N, Watanabe T, Suzuki K, et al. Risk factors predictive of lymph node metastasis in depressed early gastric carcinoma. Am J Surg. 2002;183:168–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Hochwald SN, Kim S, Klimstra DS, Brennan MF, Karpeh MS. Analysis of 154 actual 5-year survivors of gastric carcinoma. J Gastrointest Surg. 2000;4:520–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Deng J, Liang H, Sun D, Pan Y. The prognostic analysis of lymph node-positive gastric carcinoma patients following curative resection. J Surg Res. 2010;161:47–53.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yong Liu
    • 1
  • Xuegang Luo
    • 2
  • Jingyu Deng
    • 1
  • Yuan Pan
    • 1
  • Li Zhang
    • 1
  • Han Liang
    • 1
  1. 1.Department of Gastric CancerTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and TherapyTianjinChina
  2. 2.Key Laboratory of Industrial Microbiology, Ministry of Education, College of BiotechnologyTianjin University of Science and TechnologyTianjinChina

Personalised recommendations